6963-65-1

Basic information

• Product Name: 5-BROMO-4-NITRO-1H-IMIDAZOLE
• Synonyms: 5-bromo-4-nitroimidazole;4-BroMo-5-nitroiMidazole;4-Nitro-5-bromoimidazole;5(4)-Bromo-4(5)-nitroimidazole;NSC 54255
• CAS NO: 6963-65-1
• Molecular Formula: C₃H₂BrN₃O₂
• Molecular Weight: 191.9709
• Product Categories: Imidazol&Benzimidazole
• Mol File: 6963-65-1.mol
• Article Data: 7

Chemical Properties

• Melting Point: 281-282℃ (DEC.)
• Boiling Point: 382.2 °C at 760 mmHg
• Flash Point: 184.9 °C
• Appearance: /
• Density: 2.156
• Vapor Pressure: 1.06E-05mmHg at 25°C
• Refractive Index: 1.663
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 5.60±0.10(Predicted)
• CAS DataBase Reference: 5-BROMO-4-NITRO-1H-IMIDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-4-NITRO-1H-IMIDAZOLE(6963-65-1)
• EPA Substance Registry System: 5-BROMO-4-NITRO-1H-IMIDAZOLE(6963-65-1)

Safety Data

• Hazardous Substances Data: 6963-65-1(Hazardous Substances Data)

Usage

General Description

5-Bromo-4-nitro-1H-imidazole is a chemical compound that belongs to the family of imidazole derivatives. With the molecular formula C3H3BrN2O2, it consists of a five-membered heterocyclic ring containing two nitrogen atoms. 5-Bromo-4-nitro-1H-imidazole is widely used in pharmaceutical and chemical research as a building block for the synthesis of various pharmaceuticals and bioactive compounds. It has been found to exhibit antimicrobial and antifungal properties, making it a potential candidate for the development of new drugs. Additionally, 5-Bromo-4-nitro-1H-imidazole is commonly used in the field of organic synthesis as a versatile reagent for the introduction of the imidazole moiety into complex molecular structures.

InChI:InChI=1/C3H2BrN3O2/c4-2-3(7(8)9)6-1-5-2/h1H,(H,5,6)

Upstream product

• 76529-48-1 4-Iodo-5-nitroimidazole 
• 3034-38-6 5-nitro-1H-imidazole 
• 7664-93-9 sulfuric acid 
• 2302-25-2 5-bromo-1H-imidazole 
• 2302-25-2 4-bromo-1 H-imidazole 

Downstream Products

• 132747-11-6 4-Bromo-5-nitro-1-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)imidazole 
• 10512-70-6 1-(2,3,5-tri-O-acetyl-β-D-erythro-pentofuranosyl)-5-bromo-4-nitroimidazole 
• 4059-10-3 1-benzyl-5-bromo-4-nitroimidazole 
• 14953-62-9 4⁽⁵⁾-nitro-5⁽⁴⁾-phenylimidazole 
• 933-87-9 1-methyl-5-bromo-4-nitro-1H-imidazole 
• 59177-47-8 4-bromo-1-methyl-5-nitro-1H-imidazole 
• 657408-22-5 5-bromo-4-nitro-1-(3',5'-di-O-toluoyl-2'-deoxy-β-D-ribofuranosyl)imidazole 
• 6154-30-9 2,4⁽⁵⁾-dibromo-5⁽⁴⁾-nitroimidazole 
• 87243-12-7 4⁽⁵⁾-Nitro-5⁽⁴⁾-phenylaminoimidazole 
• 57531-38-1 4-chloro-5-nitroimidazole 
• 113121-61-2 5-(4'-methylphenyl)thio-4-nitroimidazole 
• 113121-80-5 4-nitro-5-phenoxyimidazole 
• 68019-78-3 4⁽⁵⁾-Nitro-5⁽⁴⁾-methoxyimidazole 
• 112995-51-4 5-bromo-4-nitro-1-phenacylimidazole 

Relevant articles and documents

Synthesis, anti-HIV-1 and antiproliferative evaluation of novel 4-nitroimidazole derivatives combined with 5-hydroxy-4-pyridinone moiety

In an effort to synthesize more effective non-nucleoside reverse transcriptase inhibitors (NNRTIs) against the HIV-1 infection, a new series of novel 4-nitroimidazole derivatives combined with 5-hydroxy-4-pyridinone moiety were designed by molecular docking studies, prepared and characterized by spectroscopic techniques. All the synthesized compounds were in vitro evaluated for their inhibitory effect against the HIV-1 replication in the MT-4 cells. Results showed that none of these synthesized compounds displayed any specific anti HIV-1 activity. Surprisingly, these compounds showed high cytotoxicity against MT-4 cells with low selectivity index (50 = 1.3 μM and EC50 = 1.8 μM respectively).

Efficient Synthesis of DNA Containing the Guanine Oxidation-Nitration Product 5-Guanidino-4-nitroimidazole: Generation by a Postsynthetic Substitution Reaction

(Matrix presented) A convertible nucleoside was synthesized and used to prepare the 2′-deoxynucleoside of 5-guanidino-4-nitroimidazole, a putative in vivo product of the reaction of peroxynitrite with guanine. The convertible nucleoside was incorporated i

Anti-infective agents

Compounds having the formula are hepatitis C (HCV) polymerase inhibitors. Also disclosed are a composition and method for inhibiting hepatitis C (HCV) polymerase, processes for making the compounds, and synthetic intermediates employed in the processes.